Chiome Bioscience Inc. [4583.T]
TOKYO, Jun 22 (Pulse News Wire) – Chiome Bioscience Inc. (4583.T) received a patent approval notification in Japan for its humanized DLK-1 antibody and FGFR4 inhibitor combination therapy.
The patent covers the use of the company's clinical-stage candidate CBA1,205 and an FGFR4 inhibitor, demonstrating strong tumor growth inhibition and reduction effects in xenograft models (Hep3B). Additionally, similar patent applications are pending in the United States, Europe, and China. The company views this patent as strengthening its intellectual property foundation supporting development and licensing activities. The approved invention pertains to cancer treatment drugs, with application number 2022-555,609. The patent holder is Chiome Bioscience Inc.
This approval is expected to have no impact on the fiscal year ending December 2026. Regarding CBA1,205, it is a humanized monoclonal antibody targeting DLK-1, an antigen found on the surface of solid tumors such as liver cancer cells. Currently, a Phase 1 domestic clinical trial is underway for patients with hepatocellular carcinoma and pediatric solid tumors. Data from this trial will inform potential licensing efforts to pharmaceutical companies. DLK-1, also known as Deltalike homolog-1, regulates the proliferation and differentiation of immature cells like stem cells and progenitor cells.
Its presence on liver cancer cell surfaces suggests potential as a target for cancer therapies.
🟢 Confidence: High AI-translated content.